07:00 , Sep 10, 2015 |  BC Innovations  |  Tools & Techniques

Testing animals like humans

A group of six European labs has banded together to test the idea that carrying out preclinical studies more like trials in humans could reduce the variability seen as one of the key facets of...
08:00 , Feb 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Sirtuin 3 (SIRT3); AMP-activated protein kinase (AMPK)

Renal disease INDICATION: Renal damage Mouse and cell culture studies suggest SIRT3 could help prevent acute kidney injury (AKI). In cisplatin-treated mice, upregulation of SIRT3 expression with an AMPK agonist or an antioxidant decreased cisplatin-induced...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Clinical News

Emapticap pegol: Phase IIa data

A double-blind, international Phase IIa trial in 75 Type II diabetics with albuminuria on current standard of care to control hypertension, hyperglycemia and dyslipidemia showed that twice-weekly 0.5 mg/kg subcutaneous NOX-E36 met the primary endpoint...
00:17 , Apr 5, 2014 |  BC Extra  |  Clinical News

Noxxon's NOX-E36 meets in diabetic nephropathy trial

Noxxon Pharma AG (Berlin, Germany) said twice-weekly subcutaneous NOX-E36 met the primary endpoint vs. placebo in a Phase IIa trial to treat diabetic nephropathy. NOX-E36 reduced urinary albumin excretion as measured by the change from...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Financial News

VistaGen proposes private placement

VistaGen Therapeutics Inc. (OTCBB:VSTA), South San Francisco, Calif.   Business: ADMET, Gene/Cell therapy, Neurology   Date announced: 4/10/13   Type: Private placement   To be raised: $36 million   Shares: 72 million   Price: $0.50...
07:00 , Apr 15, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) jumped $5.13 (64%) to $13.10 on Thursday after announcing that FDA said existing data, including a single Phase III trial, were sufficient to support an NDA for pimavanserin to...
00:34 , Apr 11, 2013 |  BC Extra  |  Financial News

VistaGen to raise $36M from Bergamo

VistaGen Therapeutics Inc. (OTCBB:VSTA) plans to raise $36 million through the sale of 72 million shares at $0.50 in a private placement to holding company Bergamo Acquisition Corp. (Pink:BGMO). The price is a 34% discount...
07:00 , Apr 30, 2012 |  BioCentury  |  Finance

Turkish injection

For the second April in a row, Amgen Inc. (NASDAQ:AMGN) has dipped into an emerging market via M&A. This time, it is buying Mustafa Nevzat Pharmaceuticals A.S. for a valuation that is 3.5x its 2011...
08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Living creatively

For small, early stage biotech companies, 2012 could be the year of living creatively. Although public biotechs raised more funds last year than ever before, the vast majority of the money was debt financing by...
08:00 , Jan 2, 2012 |  BioCentury  |  Strategy

Elementary, Watson

Amgen Inc. is banking on the combination of its 30 years in the branded biologics business and Watson Pharmaceuticals Inc. 's commercial experience with generics to give the partners a leg up in a space...